Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?

被引：6
|
作者：
Kirby, Roger S. [1 ]
Carson, Culley, III [3 ]
Dasgupta, Prokar [1 ,2 ]
机构：
[1] Kings Coll London, Guys Hosp, Prostate Ctr, London WC2R 2LS, England
[2] Kings Coll London, Guys Hosp, Dept Urol, London WC2R 2LS, England
[3] Univ N Carolina, Dept Urol, Chapel Hill, NC USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷 / 05期
关键词：
treatment for prostatitis; tadalafil; 5; mg; pelvic pain; prostatitis; ERECTILE DYSFUNCTION; TADALAFIL; PROSTATITIS; MECHANISM; SYMPTOMS; LUTS; BPH;
D O I：
10.1111/bju.12681
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：694 / 695
页数：2
相关论文
共 50 条
  • [31] Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation
    Cimen, Sertac
    Demir, Omer
    Aslan, Guven
    Esen, Ahmet Adil
    AGING MALE, 2009, 12 (2-3) : 58 - 61
  • [32] Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment
    Loeb, Stacy
    Folkvaljon, Yasin
    Robinson, David
    Schlomm, Thorsten
    Garmo, Hans
    Stattin, Par
    EUROPEAN UROLOGY, 2016, 70 (05) : 824 - 828
  • [33] Predictors of Phosphodiesterase Type 5 Inhibitor Treatment Failure in Patients Diagnosed With Erectile Dysfunction
    Albarakati, Muath
    El-Tholoth, Hossam S.
    Alzahrani, Abdulaziz
    Alghamdi, Omar S.
    Alquliti, Abdulrahman
    Alnuami, Musa
    Althobity, Abdalmagid
    Almardawi, Abdulmalik
    Bedaiwi, Khaled
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [34] Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study
    Mirone, Vincenzo
    Bianca, Roberta d'Emmanuele di Villa
    Mitidieri, Emma
    Imbimbo, Ciro
    Fusco, Ferdinando
    Verze, Paolo
    Vitale, Dino F.
    Sorrentino, Raffaella
    Cirino, Giuseppe
    EUROPEAN UROLOGY, 2009, 56 (06) : 1067 - 1073
  • [35] Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study
    Rosenberg, M. T.
    Adams, P. L.
    McBride, T. A.
    Roberts, J. N.
    McCallum, S. W.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) : 27 - 34
  • [36] Patients responding to phosphodiesterase type 5 inhibitor therapy - What do their sexual partners know?
    Klotz, Theodor
    Mathers, Mike
    Klotz, Rosemarie
    Sommer, Frank
    JOURNAL OF SEXUAL MEDICINE, 2007, 4 (01) : 162 - 165
  • [37] Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK
    Kell, Philip D.
    Hvidsten, Kyle
    Morant, Steven V.
    Harnett, James P.
    Bridge, Sarah
    BJU INTERNATIONAL, 2007, 99 (04) : 860 - 863
  • [38] Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension
    Kilickesmez, Kadriye
    Kucukoglu, M. Serdar
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2010, 10 : 16 - 18
  • [39] Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease
    Fiorito, Jole
    Saeed, Faisal
    Zhang, Hong
    Staniszewski, Agnieszka
    Feng, Yan
    Francis, Yitshak I.
    Rao, Sudha
    Thakkar, Devarshi M.
    Deng, Shi-Xian
    Landry, Donald W.
    Arancio, Ottavio
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 60 : 285 - 294
  • [40] Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction
    Limin, Ma
    Johnsen, Niels
    Hellstrom, Wayne J. G.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (11) : 1427 - 1437
12345